Bio-Plex Multiplex SARS-CoV-2 Serology and Neutralization Assays

Bio-Plex Pro Human SARS-CoV-2 Neutralization Antibody Assays

Product Information Sheet

See Performance Data
Bio-Plex Pro SARS-CoV-2 Multiplex Serology Assays Flier

Bio-Plex Pro SARS-CoV-2 Multiplex Serology Assays Flier

Download Flier

The Bio-Plex Pro SARS-CoV-2 Serology Assays* provide COVID-19 researchers with sensitive and specific assays to monitor the antibody immune response profile against four viral antigens. There are three isotype-specific 4-plex panels that measure antibodies against SARS-CoV-2 Nucleocapsid, Receptor Binding Domain, Spike 1, and Spike 2 viral proteins. The isotype-specific antibodies detected are IgA, IgG, and IgM, providing the spectrum of humoral response over time after COVID-19 vaccine administration or natural exposure to SARS-CoV-2.

Serology Assays Ordering Information »

Bio-Plex Pro SARS-CoV-2 neutralization assays allow researchers to assess the efficacy of COVID-19 vaccines and compare effectiveness of naturally acquired or vaccine-induced antibody response to arising variants of concern. These highly precise and sensitive assays quantitatively measure SARS-CoV-2 neutralizing antibodies against two wild type and 11 variants of receptor binding domain and spike 1 protein subunits. Antigens are coated on magnetic beads that bind neutralizing antibodies in competition with a biotinylated detection ACE-2 receptor.

SARS-CoV-2 Wild Type and Variant S1 and RBD Antigens

    • Wild type RBD
    • Wild type S1
    • Alpha S1
    • Beta S1
    • Gamma RBD
    • Delta RBD
    • Delta Spike Trimer
    • Epsilon RBD
    • Kappa RBD
    • D614G S1
    • N501Y RBD
    • K417N RBD
    • E484K RBD

In this rapidly changing SARS-CoV-2 variant landscape, the Bio-Plex Human SARS-CoV-2 Neutralization Antibody Custom Assay Developer Kit, can be used to develop neutralization assays with any variant of interest. It comes with the Bio-Plex Pro Amine Coupling Kit, a vial of Bio-Plex Pro Magnetic COOH Beads 27, and Bio-Plex Pro Serology Beads Storage Buffer.

Individual assay components are also available, offering the flexibility to assay only the IgA, IgG, IgM, or neutralization antibodies of interest. The viral-protein coated beads can be used to assay antibodies specific to SARS-CoV-2 in multiple species and only need to be paired with a species-specific biotinylated detection antibody for the serology assays. Bio-Plex Pro reagent kits can be used to further streamline assay configuration.

Individual Assay Component Ordering Information »

* Bio-Plex Pro SARS-CoV-2 Serology Assays are for research use only.​ Not for use in diagnostic procedures.

COVID-19 Vaccine Research and Development and Clinical Trials

The immune response to vaccination is multifaceted, with elements of the innate and adaptive immune response reacting to the target immunogen. Capturing the antibody response is one aspect that can be used to determine a vaccine's efficacy.

The Bio-Plex SARS-CoV-2 serology and neutralization assays enable you to:

  • Detect antibody response to specific viral subunits and quantitatively measure neutralizing antibodies to understand each protein’s immunogenicity profile
  • Monitor dosing levels and efficacy in preclinical and clinical trials
  • Determine effectiveness of vaccine over time through seropositive results during post-market surveillance
Vaccine workflow

IgA, IgG, and IgM Multiplex Serology and Neutralization Assay Kits

Serology Assays: SARS-CoV-2 N, RBD, S1, and S2 Coupled Beads​ and Neutralization Assays: SARS-CoV-2 RBD and S1 Wild Type and Variant Coupled Beads

Serology Assays: Anti-IgA, IgG, and IgM Antibodies and Neutralization Assays: Detection ACE-2 Receptor​

Serology Assays: Control Sets and Neutralization Assays: Standard and Control

Reagent Kits 

​*Researcher provides species-specific detection antibody and controls for animal models​

Publications For Multiplex Immunoassay Use in Vaccine Development

  1. Trivedi SU, Miao C, Sanchez JE, Caidi H, Tamin A, Haynes L, Thornburg NJ. Development and Evaluation of a Multiplexed Immunoassay for Simultaneous Detection of Serum IgG Antibodies to Six Human Coronaviruses. Sci Rep. 2019 Feb 4;9(1):1390. DOI: 10.1038/s41598-018-37747-5
  2. Itell HL et al. (2018) Development and application of a multiplex assay for the simultaneous measurement of antibody responses elicited by common childhood vaccines. Vaccine. 2018 Sep 5;36(37):5600-5608. DOI: 10.1016/j.vaccine.2018.07.048
  3. Nygård M et al. (2018) Evaluation of the Long-Term Anti-Human Papillomavirus 6 (HPV6), 11, 16, and 18 Immune Responses Generated by the Quadrivalent HPV Vaccine. Clin Vaccine Immunol. 2015 Aug;22(8):943-8. DOI: 10.1128/CVI.00133-15

See Full Publications List »

SARS-CoV-2 Antibody Assays for Public Health Studies

Surveillance Workflow

Surveying the seroprevalence of antibodies to the SARS-CoV-2 virus is key to understanding local infection and exposure rates in specific areas or institutions. Because some people are asymptomatic and may not know they have been infected, population studies are crucial in modeling transmission in the COVID-19 pandemic.

Bio-Plex SARS-CoV-2 Antibody Assays provide flexible options to measure anti-SARS-CoV-2 IgG antibodies in a population. Samples can be assayed to measure any combination of antibodies against SARS-CoV-2 nucleocapsid, receptor-binding domain, spike 1, and spike 2 viral proteins.

Publications For Multiplex Immunoassay Use in Seroprevalence Studies

  1. Fenwick C et al. (2020) Changes in SARS-CoV-2 Antibody Responses Impact the Estimates of Infections in Population-Based Seroprevalence Studies. medRxiv 2020.07.14.20153536; DOI: 10.1101/2020.07.14.20153536
  2. Kamminga S (2018) Seroprevalence of fourteen human polyomaviruses determined in blood donors. PLoS One. 2018 Oct 23;13(10):e0206273. DOI: 10.1371/journal.pone.0206273
  3. Kaur H et al. (2018) Evaluation of the reproducibility of a serological test for antibodies to Chlamydia trachomatis pgp3: A potential surveillance tool for trachoma programs. J Microbiol Methods. 2018 Apr;147:56-58. DOI: 10.1016/j.mimet.2018.02.017

See Full Publications List »

Bio-Plex SARS-CoV-2 Assays Ordering Options

Multiplex SARS-CoV-2 Assay Human Serology Kits

Multiplex SARS-CoV-2 Serology and Neutralization Ab Assays Kits

Select complete, ready-to-use kits for multiplex target panels. For human samples only.

Individual SARS-CoV-2 Assay Components

Individual SARS-CoV-2 Serology and Neutralization Ab Assays Components

Measure individual SARS-CoV-2 isotype specific antibodies and neutralizing antibodies. Viral protein coupled beads can be used for human samples and other species.

SARS-CoV-2 Assay Documents & Resources

BioRad Serology eBook

NEW COVID-19 eBook

Sero-Surveillance: Immunoassays for Combating the COVID-19 Pandemic




  • Role of Aberrant Cytokine Activity in Host Immune Response to COVID-19

    Role of Aberrant Cytokine Activity in Host Immune Response to COVID-19

    In this webinar, we discuss early research and nascent hypotheses regarding the pathophysiology of SARS-CoV-2 induced COVID-19 disease by evaluating cytokine and chemokine profiles, the role of chronic inflammation in comorbidities, and the arc of immune resolution of historical virulent pathogens, such as SARS and MERS.

  • Multiplex Immunoassays in Vaccine Research and Development

    Multiplex Immunoassays in Vaccine Research and Development

    Get the most data out of your sample, without spending time on individual ELISAs. Learn how multiplex assays are being used on the front lines to understand patient immune response during infection, and discuss the most commonly asked questions around targets, panels, and multi-plate data analysis.

  • Vaccine Development and Manufacturing

    Vaccine Development and Manufacturing

    Tips for overcoming developmental hurdles, technologies that can shorten timelines, and novel tools for manufacturing and quality control.

  • Immunological Response Factors to SARS‑CoV‑2 in Acquired Immunity

    Immunological Response Factors to SARS‑CoV‑2 in Acquired Immunity

    In this webinar, we will be discussing the immune response to SARS‑CoV-2, both in the context of natural exposure to the virus as well as induced immunity from vaccination. We will also investigate the relationship between symptom severity and the longevity of acquired immunity.

Related Products